

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/533,160-Conf. #7155
				Filing Date	October 12, 2005
				First Named Inventor	Werner Gehringer
				Art Unit	1656
				Examiner Name	K. C. Carlson
Sheet	1	of	1	Attorney Docket Number	37998-237519

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/KCC/	CA	CHE, Y. et al., "Impact of Manufacturing Improvements on Clinical Safety of Albumin; Australian Pharmacovigilance Data for 1988-2005", <u>Critical Care and Resuscitation</u> , Vol 8, No. 4, December 2006,	
/KCC/	CB	KERRY, P.J., et al. "Standardization of Prekallikrein Activator (PKA): The 1st International Standard for PKA", <u>National Institute for Biological Standards and Control, London</u> , October 22, 1984	
/KCC/	CC	"Albumin Soltion, Human", <u>European Pharmacopoeia</u> , 1997	
/KCC/	CD	"Human Albumin 20% Immuno. Human Albumin 25% Immuno", <u>Immuno AG</u> , August 1990,	

Examiner Signature	/Karen Cochrane Carlson/ (11/17/2009)	Date Considered	
-----------------------	---------------------------------------	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.